A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza - Trial NCT06094010
Access comprehensive clinical trial information for NCT06094010 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Influenza. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hoffmann-La Roche
Timeline & Enrollment
Phase 3
Nov 30, 2023
Jun 30, 2027
Primary Outcome
Percentage of Participants with Resistance-Associated Pre-Treatment Substitutions,Percentage of Participants with Resistance-Associated Treatment-Emergent Substitutions
Summary
The purpose of this study is to evaluate the pre-treatment and single-dose post treatment
 susceptibility of baloxavir marboxil in participants aged 1 to 12 years with influenza.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06094010
Non-Device Trial